QIACUITYDX
LIVE

Serial Number

79406403

Owner

QIAGEN GmbH

Attorney

G MATHEW LOMBARD

Filing Date

Jul 25, 2024

Add to watchlist:

No watchlists yet
View on USPTO

QIACUITYDX Trademark

Serial Number: 79406403 • Registration: 7979778

QIACUITYDX is a trademark filed by QIAGEN GmbH on July 25, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

QIAGEN GmbH

QIAGEN Straße 1
Hilden 40724 , DE

Entity Type: 99

Trademark Details

Filing Date

July 25, 2024

Registration Date

October 14, 2025

Published for Opposition

August 26, 2025

Goods & Services

Testing services, namely, quantifying DNA and RNA for medical, diagnostic and treatment purposes; rental of digital Polymerase Chain Reaction (PCR) apparatus; RNA or DNA analysis for cancer diagnosis and prognosis; Medical services, in particular medical analysis in connection with the treatment of individuals; providing information in the fields of medicine, veterinary medicine and pharmaceuticals; health centers, namely, genetic centers providing medical diagnostic, preventive and curative therapy services for genetic disorders, cancer treatment centers, rare disease treatment centers, children's hospitals and women's hospital; medical clinics; gene therapy services in the field of oncology, infertility, prenatal diagnostics, carrier testing, and genetically inherited diseases; medical laboratory services for the analysis of samples taken from patients.

Apparatus for medical and veterinary diagnostic analysis and determination of medical and veterinary conditions, namely DNA and RNA testing apparatus; Medical and veterinary equipment for diagnostic purposes; clinical medical laboratory apparatus and analytical instruments, namely digital Polymerase Chain Reaction (d PCR) instruments for use in in-vitro and in-vivo diagnostics; medical devices for detection of infectious disease, namely, digital polymerase chain reaction (dPCR) platforms; medical devices for use in pre-natal screenings, namely, digital polymerase chain reaction (dPCR) platform; medical devices, namely, digital polymerase chain reaction (dPCR) instruments for use in detecting, diagnosing and treating cancer and infectious disease, namely, digital polymerase chain reaction (dPCR) platform; medical devices, namely, digital polymerase chain reaction (dPCR) instruments for use in pre-natal screenings, namely, digital polymerase chain reaction (PCR) platform; medical devices, namely, instruments for use in measuring and quantifying copy number of DNA for medical diagnostic purposes, namely, digital polymerase chain reaction (dPCR) platform; microfluidic plates for use as medical apparatus.

Diagnostic preparations for medical or veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, in particular diagnostics, for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids; chemical, biochemical and biotechnological preparations for medical and veterinary purposes, in particular reagents, enzymes and buffer solutions for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids, in particular reagents, enzymes and buffer solutions for nucleic acid amplification; kits containing preparations for medical and veterinary diagnostic purposes, in particular for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids, in particular reagents, enzymes and buffer solutions for nucleic acid amplification; chemical reagents for medical purposes; cartridges containing medical diagnostic reagents for use in Polymerase Chain Reaction (PCR) or digital Polymerase Chain Reaction (PCR) instruments; medical diagnostic assays for testing of body samples, including bodily fluids and tissue in the detection, monitoring, and prediction of disease or other conditions, disease states, hormone level, drug level, drug response, organ function effectiveness, and clinical response; diagnostic test kits comprised of medical diagnostic reagents and assays for testing in the field of medical diagnostics.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 7, 2026 FINV
FINAL DISPOSITION NOTICE SENT TO IB
Apr 23, 2026 FICS
FINAL DISPOSITION PROCESSED
Apr 22, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 26, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 9, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 9, 2026 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 14, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 14, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 14, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 26, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 26, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 20, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 23, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 16, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 16, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 16, 2025 TROA
REFUSAL PROCESSED BY IB
Mar 29, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 11, 2025 RFCS
REFUSAL PROCESSED BY MPU
Mar 11, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 23, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jan 22, 2025 CNRT
ASSIGNED TO EXAMINER
Jan 13, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 13, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 13, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 10, 2024 REPR